Das Klinikum

Dr. Annika Nelde

Dr. Annika Nelde

Bereichsleitung Forschung

Kontakt

Telefonnummer: 07071 29-78685

E-Mail-Adresse: annika.nelde@uni-tuebingen.de

Klinik / Institut / Zentrum

  • 2020 Dissertation award of the Reinhold-und-Maria-Teufel-Stiftung
  • 2018 Young Investigators' Award DGHO
  • 2018 Poster price DGHO
  • 2015 Abstract Achievement Award American Society of Hematology
  • Nelde A, Schuster H, Heitmann JS, Bauer J, Maringer Y, Zwick M, Volkmer JP, Chen JY, Stanger AMP, Lehmann A, Appiah B, Märklin M, Rücker-Braun E, Salih HR, Roerden M, Schroeder SM, Häring MF, Schlosser A, Schetelig J, Schmitz M, Boerries M, Köhler N, Lengerke C, Majeti R, Weissman IL, Rammensee HG, Walz JS. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Blood Cancer Discov (2023)
  • Seller A, Hackenbruch C, Walz JS, Nelde A, Heitmann JS. Long-Term Follow-Up of COVID-19 Convalescents-Immune Response Associated with Reinfection Rate and Symptoms. Viruses (2023)
  • Heitmann JS*, Tandler C*, Marconato M*, Nelde A*, Habibzada T, Rittig SM, Tegeler CM, Maringer Y, Jaeger SU, Denk M, Richter M, Oezbek MT, Wiesmüller KH, Bauer J, Rieth J, Wacker M, Schroeder SM, Hoenisch Gravel N, Scheid J, Märklin M, Henrich A, Klimovich B, Clar KL, Lutz M, Holzmayer S, Hörber S, Peter A, Meisner C, Fischer I, Löffler MW, Peuker CA, Habringer S, Goetze TO, Jäger E, Rammensee HG, Salih HR, Walz JS. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency. Nat Commun (2023). *Authors contributed equally to this work.
  • Wacker M, Bauer J, Wessling L, Dubbelaar M, Nelde A, Rammensee HG, Walz JS. Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics. Front Immunol (2023)
  • Hackenbruch C, Maringer Y, Tegeler CM, Walz JS, Nelde A, Heitmann JS. Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome. Viruses (2023)
  • Schroeder SM, Nelde A, Walz JS. Viral T-cell epitopes - Identification, characterization and clinical application. Semin Immunol (2023)
  • Junker D, Becker M, Wagner TR, Kaiser PD, Maier S, Grimm TM, Griesbaum J, Marsall P, Gruber J, Traenkle B, Heinzel C, Pinilla YT, Held J, Fendel R, Kreidenweiss A, Nelde A, Maringer Y, Schroeder S, Walz JS, Althaus K, Uzun G, Mikus M, Bakchoul T, Schenke-Layland K, Bunk S, Haeberle H, Göpel S, Bitzer M, Renk H, Remppis J, Engel C, Franz AR, Harries M, Kessel B, Lange B, Strengert M, Krause G, Zeck A, Rothbauer U, Dulovic A, Schneiderhan-Marra N. Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants. Clin Infect Dis (2023)
  • Maringer Y, Nelde A, Schroeder SM, Schuhmacher J, Hörber S, Peter A, Karbach J, Jäger E, Walz JS. Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Sci Immunol (2022)
  • Nelde A, Rieth J, Roerden M, Dubbelaar ML, Hoenisch Gravel N, Bauer J, Klein R, Hoheisel T, Mahrhofer H, Göpel S, Bitzer M, Hörber S, Peter A, Heitmann JS, Walz JS. Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity. iScience (2022)
  • Bauer J, Köhler N, Maringer Y, Bucher P, Bilich T, Zwick M, Dicks S, Nelde A, Dubbelaar M, Scheid J, Wacker M, Heitmann JS, Schroeder S, Rieth J, Denk M, Richter M, Klein R, Bonzheim I, Luibrand J, Holzer U, Ebinger M, Brecht IB, Bitzer M, Boerries M, Feucht J, Salih HR, Rammensee HG, Hailfinger S, Walz JS. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun (2022)
  • Marconato M, Maringer Y, Walz JS, Nelde A, Heitmann JS. Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome. Cancers (Basel) (2022)
  • Tegeler CM, Bilich T, Maringer Y, Salih HR, Walz JS, Nelde A, Heitmann JS. Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort. Int J Infect Dis (2022)
  • Tegeler CM, Scheid J, Rammensee HG, Salih HR, Walz JS, Heitmann JS, Nelde A. HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients. Cancers (Basel) (2022)
  • Nelde A*, Flötotto L*, Jürgens L, Szymik L, Hubert E, Bauer J, Schliemann C, Kessler T, Lenz G, Rammensee HG, Walz JS, Wethmar K. Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens. Cell Mol Life Sci (2022). *Authors contributed equally to this work.
  • Heitmann JS*, Bilich T*, Tandler C*, Nelde A, Maringer Y, Marconato M, Reusch J, Jäger S, Denk M, Richter M, Anton L, Weber LM, Roerden M, Bauer J, Rieth J, Wacker M, Hörber S, Peter A, Meisner C, Fischer I, Löffler MW, Karbach J, Jäger E, Klein R, Rammensee HG, Salih HR, Walz JS. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature (2021) *Authors contributed equally to this work.
  • Brunk F*, Moritz A*, Nelde A*, Bilich T, Casadei N, Fraschka SA, Heitmann JS, Hörber S, Peter A, Rammensee HG, Singh H, Walz JS, Maurer D, Wagner C. SARS‐CoV‐2‐reactive T cell receptors isolated from convalescent COVID‐19 patients confer potent T cell effector function. European Journal of Immunology (2021)
  • Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar ML, Peter A, Horber S, Bauer J, Rieth J, Wacker M, Berner F, Flatz L, Held S, Brossart P, Märklin M, Wagner P, Erne E, Klein R, Rammensee H-G, Salih HR, Walz JS. Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. Cancer Discovery (2021)
  • Nelde A*, Maringer Y*, Bilich T, Salih HR, Roerden M, Heitmann JS, Marcu A, Bauer J, Neidert MC, Denzlinger C, Illerhaus G, Aulitzky WE, Rammensee HG, Walz JS. Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia. Front Immunol (2021) *Authors contributed equally to this work.
  • Rammensee HG, Gouttefangeas C, Heidu S, Klein R, Preuß B, Walz JS, Nelde A, Haen SP, Reth M, Yang J, Tabatabai G, Bösmüller H, Hoffmann H, Schindler M, Planz O, Wiesmüller KH, Löffler MW. Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups. Vaccines (Basel) (2021)
  • Wagner TR, Ostertag E, Kaiser PD, Gramlich M, Ruetalo N, Junker D, Haering J, Traenkle B, Becker M, Dulovic A, Schweizer H, Nueske S, Scholz A, Zeck A, Schenke-Layland K, Nelde A, Strengert M, Walz JS, Zocher G, Stehle T, Schindler M, Schneiderhan-Marra N, Rothbauer U. NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies. EMBO Rep (2021)
  • Fink S, Ruoff F, Stahl A, Becker M, Kaiser P, Traenkle B, Junker D, Weise F, Ruetalo N, Hörber S, Peter A, Nelde A, Walz J, Krause G, Baillot A, Schenke-Layland K, Joos TO, Rothbauer U, Schneiderhan-Marra N, Schindler M, Templin MF. Multiplexed Serum Antibody Screening Platform Using Virus Extracts from Endemic Coronaviridae and SARS-CoV-2. ACS Infect Dis (2021)
  • Bilich T*, Nelde A*, Heitmann JS*, Maringer Y, Roerden M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Rachfalski D, Märklin M, Stevanović S, Rammensee HG, Salih HR, Walz JS. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Sci Transl Med (2021) *Authors contributed equally to this work.
  • Becker M, Strengert M, Junker D, Kaiser PD, Kerrinnes T, Traenkle B, Dinter H, Häring J, Ghozzi S, Zeck A, Weise F, Peter A, Hörber S, Fink S, Ruoff F, Dulovic A, Bakchoul T, Baillot A, Lohse S, Cornberg M, Illig T, Gottlieb J, Smola S, Karch A, Berger K, Rammensee HG, Schenke-Layland K, Nelde A, Märklin M, Heitmann JS, Walz JS, Templin M, Joos TO, Rothbauer U, Krause G, Schneiderhan-Marra N. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Nat Commun (2021)
  • Nelde A, Rammensee H-G, Walz JS. The peptide vaccine of the future. Molecular & Cellular Proteomics (2021)
  • Huergo LF, Selim KA, Conzentino MS, Gerhardt ECM, Santos ARS, Wagner B, Alford JT, Deobald N, Pedrosa FO, de Souza EM, Nogueira MB, Raboni SM, Souto D, Rego FGM, Zanette DL, Aoki MN, Nardin JM, Fornazari B, Morales HMP, Borges VA, Nelde A, Walz JS, Becker M, Schneiderhan-Marra N, Rothbauer U, Reis RA, Forchhammer K. Magnetic Bead-Based Immunoassay Allows Rapid, Inexpensive, and Quantitative Detection of Human SARS-CoV-2 Antibodies. ACS Sens (2021)
  • Nelde A*, Bilich T*, Heitmann JS*, Maringer Y, Salih HR, Roerden M, Lübke M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Traenkle B, Kaiser PD, Rothbauer U, Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jäger E, Graf M, Gruber LC, Rachfalski D, Preuß B, Hagelstein I, Märklin M, Bakchoul T, Gouttefangeas C, Kohlbacher O, Klein R, Stevanović S, Rammensee HG, Walz JS. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T-cell recognition. Nature Immunology (2020). *Authors contributed equally to this work.
  • Roerden M, Nelde A, Heitmann JS, Klein R, Rammensee HG, Bethge WA, Walz JS. HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation. Cancers. (2020)
  • Ziegler M, Nelde A, Weber JK, Schreitmüller C, Martrus G, Huynh T, Bunders MJ, Lunemann S, Stevanović S, Zhou R, Altfeld M. HIV-1-induced changes in HLA C*03:04-presented peptide repertoires lead to reduced engagement of inhibitory NK cell receptors. AIDS. (2020)
  • Reustle A, Di Marco M, Meyerhoff C, Nelde A, Walz JS, Winter S, Kandabarau S, Büttner F, Haag M, Backert L, Kowalewski DJ, Rausch S, Hennenlotter J, Stühler V, Scharpf M, Fend F, Stenzl A, Rammensee HG, Bedke J, Stevanović S, Schwab M, Schaeffeler E. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Med: 12(1):32 (2020)
  • Teck AT, Urban S, Quass P, Nelde A, Schuster H, Letsch A, Busse A, Walz JS, Keilholz U, Ochsenreither S. Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo. Cancer Immunol Immunother. (2020)
  • Bilich T, Nelde A, Bauer J, Walz S, Roerden M, Salih HR, Weisel K, Besemer B, Marcu A, Lübke M, Schuhmacher J, Neidert MC, Rammensee HG, Stevanović S, Walz JS. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. Blood Cancer J: 10(2): 24 (2020)
  • Ghosh M, Gauger M, Marcu A, Nelde A, Denk M, Schuster H, Rammensee HG, Stevanović S. Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies. Mol Cell Proteomics: 19(3):432-443 (2020)
  • Roerden M, Nelde A, Walz JS. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy? Front Immunol: 10:3004 (2019)
  • Lübke M, Spalt S, Kowalewski DJ, Zimmermann C, Bauersfeld L, Nelde A, Bichmann L, Marcu A, Peper JK, Kohlbacher O, Walz JS, Le-Trilling VTK, Hengel H, Rammensee HG, Stevanović S, Halenius A.Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models. J Exp Med: 217(3) (2020)
  • Bichmann L, Nelde A, Ghosh M, Mohr C, Peltzer A, Kuchenbecker L, Heumos L, Sachsenberg T, Walz JS, Stevanović S, Rammensee H-G, and Kohlbacher O. MHCquant: Automated and reproducible data analysis for immunopeptidomics. Journal of Proteome Research: 8(11):3876-3884 (2019)
  • Nelde A, Kowalewski DJ, and Stevanović S. Purification and Identification of Naturally Presented MHC Class I and II Ligands. Antigen Processing: 123-136 (2019).
  • Bauer J, Nelde A, Bilich T, and Walz JS. Antigen targets for the development of immunotherapies in leukemia. International Journal of Molecular Sciences 20 (6):1397 (2019).
  • Belnoue E, Mayol JF, Carboni S, Di Bernardino Besson W, Dupuychaffray E, Nelde A, Stevanović S, Santiago-Raber ML, Walker PR, and Derouazi M. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine. JCI Insight 4 (11): e127305 (2019).
  • Bilich T*, Nelde A*, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee H-G, Stevanović S, and Walz JS. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood 133 (6): 550-565 (2019). *Authors contributed equally to this work.
  • Walz JS, Kowalewski DJ, Backert L, Nelde A, Kohlbacher O, Weide B, Kanz L, Salih HR, Rammensee H G, and Stevanović S. Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. Leukemia and Lymphoma: 1-10 (2018).
  • Nelde A, Kowalewski DJ, Backert L, Schuster H, Werner JO, Klein R, Kohlbacher O, Kanz L, Salih HR, Rammensee H-G, Stevanović S, and Walz JS. HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. Oncoimmunology 7(4): e1316438 (2017).
  • Heidenreich F, Rücker-Braun E, Walz JS, Eugster A, Kuhn D, Dietz S, Nelde A, Tunger A, Wehner R, Link CS, Middeke JM, Stolzel F, Tonn T, Stevanović S, Rammensee H-G, Bonifacio E, Bachmann M, Zeis M, Ehninger G, Bornhauser M, Schetelig J, and Schmitz M. Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8(+) cytotoxic T cells. Haematologica 102: e460-e4 (2017).
  • Nelde A, Walz JS, Kowalewski DJ, Schuster H, Wolz OO, Peper JK, Cardona Gloria Y, Langerak AW, Muggen AF, Claus R, Bonzheim I, Fend F, Salih HR, Kanz L, Rammensee H-G, Stevanović S, and Weber AN. HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. Oncoimmunology 6: e1219825 (2017).
  • Walz S, Stickel JS, Kowalewski DJ, Schuster H, Weisel K, Backert L, Kahn S, Nelde A, Stroh T, Handel M, Kohlbacher O, Kanz L, Salih HR, Rammensee H-G, and Stevanović S. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood 126:1203-1213 (2015).
  • Publikationen